ZEB2 and ovarian carcinoma: This potential discrepancy cannot be explained by technical differences as we have confirmed the lack of GRHL2 binding in the ChIP-seq analysis by ChIP-qPCR using primers that amplified ZEB1 and ZEB2 regions bound by GRHL2 in human mammary epithelial cells and human ovarian cancer cells in other studies [17, 23].